Literature DB >> 10543673

Congenital anomalies after prenatal ecstasy exposure.

P R McElhatton, D N Bateman, C Evans, K R Pughe, S H Thomas.   

Abstract

Prospective follow-up of 136 babies exposed to ecstasy in utero indicated that the drug may be associated with a significantly increased risk of congenital defects (15.4% [95% CI 8.2-25.4]). Cardiovascular anomalies (26 per 1000 livebirths [3.0-90.0]) and musculoskeletal anomalies (38 per 1000 [8.0-109.0]) were predominant.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10543673     DOI： 10.1016/s0140-6736(99)02423-x

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  26 in total

1.  Just the berries. Ecstasy.

Authors:  Lesley Ruggles
Journal:  Can Fam Physician       Date:  2002-03       Impact factor: 3.275

Review 2.  Drugs, biogenic amine targets and the developing brain.

Authors:  Aliya L Frederick; Gregg D Stanwood
Journal:  Dev Neurosci       Date:  2009-04-17       Impact factor: 2.984

Review 3.  A developmental comparison of the neurobehavioral effects of ecstasy (MDMA).

Authors:  Brian J Piper
Journal:  Neurotoxicol Teratol       Date:  2006-10-20       Impact factor: 3.763

4.  Neurobehavioral outcomes of infants exposed to MDMA (Ecstasy) and other recreational drugs during pregnancy.

Authors:  Lynn T Singer; Derek G Moore; Sarah Fulton; Julia Goodwin; John J D Turner; Meeyoung O Min; Andrew C Parrott
Journal:  Neurotoxicol Teratol       Date:  2012-03-03       Impact factor: 3.763

5.  Treatment with MDMA from P11-20 disrupts spatial learning and path integration learning in adolescent rats but only spatial learning in older rats.

Authors:  Matthew R Skelton; Michael T Williams; Charles V Vorhees
Journal:  Psychopharmacology (Berl)       Date:  2006-10-03       Impact factor: 4.530

Review 6.  Developmental consequences of fetal exposure to drugs: what we know and what we still must learn.

Authors:  Emily J Ross; Devon L Graham; Kelli M Money; Gregg D Stanwood
Journal:  Neuropsychopharmacology       Date:  2014-06-18       Impact factor: 7.853

7.  Psychiatric profiles of mothers who take Ecstasy/MDMA during pregnancy: reduced depression 1 year after giving birth and quitting Ecstasy.

Authors:  John J D Turner; Andrew C Parrott; Julia Goodwin; Derek G Moore; Sarah Fulton; Meeyoung O Min; Lynn T Singer
Journal:  J Psychopharmacol       Date:  2013-12-10       Impact factor: 4.153

8.  Illicit drug use in late pregnancy associated with stillbirth and eclampsia.

Authors:  Katherine Scott; Narelle Fagermo; Leonie Callaway; Karin Lust
Journal:  Obstet Med       Date:  2010-09-17

9.  One-year outcomes of prenatal exposure to MDMA and other recreational drugs.

Authors:  Lynn T Singer; Derek G Moore; Meeyoung O Min; Julia Goodwin; John J D Turner; Sarah Fulton; Andrew C Parrott
Journal:  Pediatrics       Date:  2012-08-20       Impact factor: 7.124

10.  A case control study to examine the pharmacological factors underlying ventricular septal defects in the North of England.

Authors:  D N Bateman; P R McElhatton; D Dickinson; C Wren; J N S Matthews; M O'Keeffe; S H L Thomas
Journal:  Eur J Clin Pharmacol       Date:  2004-09-23       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.